Estados Unidos · Plataformas y datos · Finviz

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Publicado por Finviz · Estados Unidos hace 10 h

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a…

Leer el artículo completo en Finviz Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (elite.finviz.com)

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

También te puede interesar

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compartir

También te puede interesar

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise